- Is The Capital Ovarian Cancer Organization a tax-exempt 501(c)(3)?
- Yes. The Capital Ovarian Cancer Organization is recognised by the IRS as a 501(c)(3) organisation (EIN 41-2235692). The IRS recognised The Capital Ovarian Cancer Organization as tax-exempt in August 2007.
- What is The Capital Ovarian Cancer Organization's EIN?
- The Capital Ovarian Cancer Organization's Employer Identification Number (EIN) is 41-2235692. The EIN was assigned by the IRS in August 2007. Donors and grantmakers use the EIN to verify tax-exempt status with the IRS.
- What does The Capital Ovarian Cancer Organization do?
- Advocating and educating women and health providers to promote awareness, increase early detection, and improve treatment methods of Ovarian Cancer.
- Where is The Capital Ovarian Cancer Organization located?
- The Capital Ovarian Cancer Organization is located at PO Box 1762, Frankfort, KY, 40602.
- When was The Capital Ovarian Cancer Organization founded or recognised by the IRS?
- The Capital Ovarian Cancer Organization was recognised by the IRS as a tax-exempt organisation in August 2007. The IRS ruling date is the earliest authoritative date available for most US nonprofits.
- What is The Capital Ovarian Cancer Organization's annual revenue?
- On its most recent Form 990 (fiscal year 2024), The Capital Ovarian Cancer Organization reported $128K in total revenue and $122K in total expenses.
- Has The Capital Ovarian Cancer Organization been auto-revoked by the IRS?
- No. The Capital Ovarian Cancer Organization (EIN 41-2235692) does not appear on the IRS Auto-Revocation List. Givalgo Discover cross-references the IRS Auto-Revocation List on every profile load; if status changes, this page reflects it.
- Is The Capital Ovarian Cancer Organization listed in IRS Publication 78?
- Yes. The Capital Ovarian Cancer Organization is listed in IRS Publication 78 as an organisation eligible to receive tax-deductible charitable contributions. Pub 78 status is the canonical IRS signal that donations to an org are deductible.